Vapor Ablation for Localized Cancer Lesions of the Lung - a Clinical Feasibility Definitive Treatment Study
This study is a prospective, single-arm, multi-center, pilot trial of Bronchoscopic Thermal Vapor Ablation for Lung Cancer (BTVA-C) in patients with primary lung cancer or metastatic cancer in the lung. Patients who have consented to participate in this study (enrolled) will be subject to eligibility screening and baseline assessments, prior to undergoing the BTVA-C procedure. Only patients that meet all of the inclusion criteria and none of the exclusion criteria will receive vapor ablation treatment.
Patients will be followed for up to 12 months.
Targeted Segmental Vapor Ablation Treatment of Emphysema with Upper Lobe Predominance: a Randomized Controlled Trial of InterVapor® in France - the TARGET Trial
This study is designed to prospectively document changes in FEV1 and health-related quality of life 12 months following sequential segmental treatment with InterVapor® in patients with heterogeneous emphysema with upper lobe predominance. For validity of the study, the results will be compared to patients that receive optimal medical therapy.
Post-Market Optimization Study of the EMPOWER® RF Catheter to Ablate Soft Tissue Lesions in the Lung
A post-market study to assess the performance and safety of a RF ablation catheter to bronchoscopically ablate lung lesions will be evaluated in patients with confirmed diagnosis of non-small cell lung cancer or metastatic lung lesions who are scheduled for surgical resection.
100 项与 Uptake Medical Technology, Inc. 相关的临床结果
0 项与 Uptake Medical Technology, Inc. 相关的专利(医药)
100 项与 Uptake Medical Technology, Inc. 相关的药物交易
100 项与 Uptake Medical Technology, Inc. 相关的转化医学